Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 13/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 13/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 13/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 13/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 13/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.35 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26549131 | 0.91 | MAOA (0.34) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL24317122 | 0.90 | CTSD (0.40) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL24316602 | 0.87 | CREBBP (0.40) | PIK3CD | |
| SCHEMBL29471215 | 0.87 | CREBBP (0.40) | PIK3CD | |
| SCHEMBL24317131 | 0.87 | EGFR (0.32) | MAOA | |
| SCHEMBL24316774 | 0.87 | PRKDC (0.36) | MAOA | |
| SCHEMBL24317120 | 0.86 | FGFR1 (0.32) | MAOA | |
| SCHEMBL24317119 | 0.84 | POLB (0.34) | KDM4E | |
| SCHEMBL24316863 | 0.83 | CFTR (0.36) | MAOA | |
| SCHEMBL24317132 | 0.82 | SLC6A4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | GABRA1 1765/4885GABRG2 2206/4885GABRB3 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.